Tenderwize
Back to tender search

Discount Agreement for Doravirin/Lamivudin/Tenofovir

Techniker Krankenkasse·Hamburg, Germany·Deadline Nov 29, 2027 · 465 days left·Open·Supplies
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-32 - Doravirin/Lamivudin/Tenofovir (Wirkstoffkombination)

30/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

30 / 100

Complexity

20 / 100

Risk factors

No estimated value or volume guarantees; uncertain revenue potential.

Contract terminates automatically on patent/market exclusivity expiry, possibly before end of term.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Nov 2027
  • Supply of pharmaceutical product Doravirin/Lamivudin/Tenofovir
  • Enter into a discount agreement (Rabattvertrag) with TK
Show full summary

This is an Open House procedure by Techniker Krankenkasse (TK) for concluding discount agreements (Rabattverträge) for the drug combination Doravirin/Lamivudin/Tenofovir. No estimated value is provided. The procedure is open to all eligible pharmaceutical manufacturers meeting specific criteria. Contracts are non-exclusive, with a maximum term of 24 months ending 30 November 2027. Joining is possible at any time during the term. No award criteria apply; any qualifying supplier will be accepted.

Risks

No estimated value or volume guarantees; uncertain revenue potential.

Contract terminates automatically on patent/market exclusivity expiry, possibly before end of term.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical manufacturer (pharmazeutischer Unternehmer) as per §4(18) AMG
  • Must have a valid marketing authorization for the drug combination or be authorized to market it
  • Must have seat in Germany, another EU member state, or EEA

Requirements may be incomplete.

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Discount Agreement for Doravirin/Lamivudin/Tenofovir

Conclusion of discount contracts for the drug combination Doravirin/Lamivudin/Tenofovir under §130c SGB V. Non-exclusive, standardized terms, no negotiations.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

Nov 2025 - Nov 2027

Category

Pharmaceutical products

Deadline

Deadline Nov 29, 2027

Procurement Details

Publication date
12 Oct 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
670890-2025

Documents (1)

Procurement document 1

Similar tenders

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

France – Pharmaceutical products – 26-10 : ACCORD-CADRE DE FOURNITURE DE MÉDICAMENTS 2026

Aug 21

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9